Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
LLY
Eli Lilly and Company
Drug delivery platforms are highlighted as differentiators enabling scaled manufacturing.
|
$1.05T |
$1104.95
-0.45%
|
|
REGN
Regeneron Pharmaceuticals, Inc.
Drug delivery platform concepts (e.g., formulation/formulation technologies) are implied by delivery enhancements.
|
$83.16B |
$784.81
-0.32%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
ALNY employs drug delivery platforms (e.g., GalNAc conjugates) enabling targeted and durable RNAi delivery.
|
$58.35B |
$445.07
+3.55%
|
|
BDX
Becton, Dickinson and Company
BD develops drug delivery platforms and related biologic‑delivery solutions for therapeutics including GLP‑1s and wearables.
|
$55.58B |
$193.94
-0.79%
|
|
INSM
Insmed Incorporated
ARIKAYCE uses a liposomal inhalation drug-delivery platform (Pulmovance) and TPIP is an inhaled prodrug, making Drug Delivery Platforms a core Insmed technology.
|
$43.23B |
$204.49
-2.17%
|
|
BNTX
BioNTech SE
Drug Delivery Platforms cover mRNA delivery and related platforms used to deploy therapies.
|
$24.62B |
$102.73
+3.03%
|
|
PODD
Insulet Corporation
The insulin delivery platform functions as a drug delivery platform enabled by a medical device.
|
$23.00B |
$326.89
-0.60%
|
|
ASND
Ascendis Pharma A/S
TransCon is a proprietary drug-delivery platform enabling long-acting formulations, aligning with Drug Delivery Platforms.
|
$12.08B |
$210.41
+1.82%
|
|
JAZZ
Jazz Pharmaceuticals plc
Jazz's low-sodium formulation (Xywav) reflects a Drug Delivery Platform approach.
|
$10.73B |
$176.95
-1.72%
|
|
RNA
Avidity Biosciences, Inc.
Drug Delivery Platforms: AOC platform is a delivery technology for targeting oligonucleotides to specific tissues.
|
$9.21B |
$71.58
+0.03%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.50B |
$72.68
-0.19%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.16B |
$123.82
+0.31%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
TRiM is a drug delivery platform enabling targeted siRNA delivery beyond the liver.
|
$7.98B |
$57.72
+23.36%
|
|
AXSM
Axsome Therapeutics, Inc.
MoSEIC drug-delivery platform powering Symbravo indicates reliance on Drug Delivery Platforms.
|
$7.53B |
$150.81
+0.30%
|
|
MTSR
Metsera, Inc.
HALO and MOMENTUM are proprietary drug-delivery platforms enabling extended half-life and oral peptide delivery, i.e., Drug Delivery Platforms.
|
$7.41B |
$70.53
+0.04%
|
|
STVN
Stevanato Group S.p.A.
Provides Drug Delivery Platforms as integrated containment and delivery solutions for biologics.
|
$6.94B |
$23.13
-1.07%
|
|
KRYS
Krystal Biotech, Inc.
Krystal's HSV-1 platform functions as a drug-delivery platform enabling redosable gene therapies across organs.
|
$6.33B |
$218.97
+0.92%
|
|
GKOS
Glaukos Corporation
iDose TR represents a drug delivery platform delivering a sustained intraocular Travoprost formulation.
|
$6.04B |
$105.44
+1.04%
|
|
PTGX
Protagonist Therapeutics, Inc.
Platform-based drug delivery approach enabling peptide therapeutics.
|
$5.60B |
$90.08
+0.25%
|
|
CDTX
Cidara Therapeutics, Inc.
Cloudbreak is a drug delivery platform (Drug-Fc Conjugate) enabling extended half-life and targeted activity.
|
$5.57B |
$219.76
+0.05%
|
|
ALKS
Alkermes plc
Proprietary drug delivery platforms (e.g., LinkeRx, NanoCrystal) used to create extended-release and rapid-dissolution formulations.
|
$4.91B |
$29.72
+2.52%
|
|
INDV
Indivior PLC
SUBLOCADE's extended-release delivery represents a drug delivery platform (monthly dosing), a core investable theme.
|
$4.62B |
$33.47
+1.12%
|
|
AKRO
Akero Therapeutics, Inc.
EFX is a biologic drug with a specialized delivery formulation (pre-filled syringe/lyophilized product), placing it squarely in the Drug Delivery Platforms category.
|
$4.35B |
$54.34
-0.04%
|
|
CRNX
Crinetics Pharmaceuticals, Inc.
Crinetics' NDC platform and drug-conjugate strategy reflect a drug-delivery platform providing targeted payload delivery.
|
$4.33B |
$46.05
+3.00%
|
|
SRRK
Scholar Rock Holding Corporation
Drug Delivery Platforms: platform-based approach enabling targeted modulation of growth factor signaling via antibodies.
|
$4.15B |
$43.14
+4.03%
|
|
LGND
Ligand Pharmaceuticals Incorporated
Captisol and NITRICIL are platform technologies Ligand licenses/sells to enable drug solubility and tunable dosing, constituting drug delivery platforms.
|
$4.04B |
$206.15
+1.29%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal's focus on drug delivery platforms spans multiple complex dosage forms and delivery technologies.
|
$3.93B |
$12.53
+0.68%
|
|
DYN
Dyne Therapeutics, Inc.
Dyne's FORCE platform is a drug delivery platform enabling targeted payload delivery to muscle and CNS, making it a core product category.
|
$3.01B |
$21.17
+1.78%
|
|
DNLI
Denali Therapeutics Inc.
The TransportVehicle platform is a drug delivery platform designed to cross the blood-brain barrier to deliver biologics to the CNS.
|
$2.84B |
$19.40
+1.41%
|
|
NUVB
Nuvation Bio Inc.
NUV-1511 is based on a Drug-Delivery Platform (DDC), directly describing a drug delivery platform product.
|
$2.74B |
$8.02
+1.78%
|
|
LQDA
Liquidia Corporation
Liquidia's YUTREPIA is a PRINT-enabled inhaled treprostinil, a drug-delivery platform that enables high-dose, deep-lung delivery and differentiated pharmacokinetics.
|
$2.73B |
$31.72
-1.67%
|
|
SLNO
Soleno Therapeutics, Inc.
Drug Delivery Platforms reflects VYKAT XR's extended-release formulation and dosing advantage.
|
$2.63B |
$49.59
-0.36%
|
|
SUPN
Supernus Pharmaceuticals, Inc.
Supernus leverages proprietary drug-delivery platforms, notably extended-release formulations, as a core differentiator for its CNS therapies.
|
$2.59B |
$46.27
+0.40%
|
|
BEAM
Beam Therapeutics Inc.
Beam uses lipid nanoparticle (LNP) delivery for in vivo base editing (BEAM-302, BEAM-301), i.e., a Drug Delivery Platform.
|
$2.53B |
$25.06
+1.50%
|
|
ETNB
89bio, Inc.
The company relies on a glycoPEGylation-based drug delivery platform to extend half-life and dosing convenience, representing a Drug Delivery Platforms investable theme.
|
$2.17B |
$14.85
+0.07%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$2.11B |
$12.13
+0.04%
|
|
AVDL
Avadel Pharmaceuticals plc
Avadel uses a proprietary polymer-based extended-release drug-delivery platform to create once-nightly LUMRYZ.
|
$2.08B |
$21.39
-6.69%
|
|
ZYME
Zymeworks Inc.
Drug Delivery Platforms underpin ADC and multispecific payload engineering and delivery.
|
$2.05B |
$27.34
+4.43%
|
|
SRPT
Sarepta Therapeutics, Inc.
Drug Delivery Platforms underpin Sarepta's delivery of gene therapies and RNAi assets.
|
$2.05B |
$20.97
+8.37%
|
|
ANIP
ANI Pharmaceuticals, Inc.
Development of drug delivery platforms (e.g., Cortrophin Gel pre-filled syringe) demonstrates ANI's drug delivery technology differentiators.
|
$1.83B |
$84.37
+1.38%
|
|
CLDX
Celldex Therapeutics, Inc.
Drug delivery platforms and subcutaneous formulations are part of Celldex's formulation strategy.
|
$1.78B |
$26.80
+1.34%
|
|
IMNM
Immunome, Inc.
HC74 payload and linker optimization reflect a drug delivery platform approach.
|
$1.62B |
$18.61
+1.69%
|
|
PHVS
Pharvaris N.V.
Pharvaris emphasizes oral delivery with injectable-like efficacy, indicating a Drug Delivery Platforms orientation.
|
$1.50B |
$27.80
+9.23%
|
|
URGN
UroGen Pharma Ltd.
RTGel is a drug-delivery platform used by UroGen for localized, extended-release therapy.
|
$1.36B |
$29.43
+6.28%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Drug Delivery Platforms captures Amphastar's proprietary delivery systems for injectables, inhalation, and intranasal therapies.
|
$1.27B |
$27.35
-1.23%
|
|
NKTR
Nektar Therapeutics
PEGylation is a drug-delivery platform approach used to optimize pharmacokinetics and dosing.
|
$1.25B |
$65.79
+9.01%
|
|
CVAC
CureVac N.V.
Drug Delivery Platforms captures CureVac's proprietary LNP delivery systems and thermostable formulations integral to its mRNA programs.
|
$1.23B |
$5.49
+3.98%
|
|
WVE
Wave Life Sciences Ltd.
PRISM delivers oligonucleotides via conjugates (e.g., GalNAc) and non-viral delivery, constituting a drug delivery platform.
|
$1.22B |
$7.69
+3.50%
|
|
INBX
Inhibrx Biosciences, Inc.
Drug delivery platform technology underpinning biologic therapies.
|
$1.21B |
$83.74
+1.28%
|
|
KOD
Kodiak Sciences Inc.
ABC/ABCD platforms are drug delivery technologies enabling sustained ocular release and extended durability.
|
$1.19B |
$22.44
-2.39%
|
|
XERS
Xeris Biopharma Holdings, Inc.
Xeris's XeriSol and XeriJect drug-delivery platforms enable stable, ready-to-use injectable formulations, a core differentiator.
|
$1.16B |
$7.18
+1.20%
|
|
MBX
MBX Biosciences, Inc. Common Stock
MBX is using a drug delivery platform (PEP) to extend action of peptides, enabling less frequent dosing, fitting Drug Delivery Platforms.
|
$1.14B |
$33.86
+7.15%
|
|
NVAX
Novavax, Inc.
Matrix-M is a proprietary vaccine adjuvant/drug-delivery platform used across Novavax's vaccine programs, constituting a major platform technology.
|
$1.13B |
$6.95
+3.89%
|
|
PGEN
Precigen, Inc.
Drug Delivery Platforms tag applies to platform-based delivery mechanisms like AdenoVerse and UltraCAR-T.
|
$1.11B |
$3.75
+2.18%
|
|
PVLA
Palvella Therapeutics, Inc.
QTORIN represents a drug delivery platform for localized, topical therapy, a major category in pharmaceutical technology and patient-specific treatments.
|
$1.11B |
$99.68
+5.07%
|
|
PHAT
Phathom Pharmaceuticals, Inc.
Phathom is pursuing an orally disintegrating tablet (ODT) formulation and other delivery innovations for VOQUEZNA, aligning with the drug delivery platforms investable theme.
|
$1.08B |
$15.18
+1.67%
|
|
PCRX
Pacira BioSciences, Inc.
Pacira's pMVL-based Drug Delivery Platforms enable extended-release formulations used in EXPAREL and ZILRETTA.
|
$1.07B |
$23.82
+2.78%
|
|
OPK
OPKO Health, Inc.
Entera Bio collaboration for oral formulation indicates an emphasis on drug delivery platforms.
|
$1.06B |
$1.35
|
|
EYPT
EyePoint Pharmaceuticals, Inc.
Core platform technology (Durasert E) used for sustained ocular drug delivery.
|
$1.02B |
$14.78
+0.24%
|
|
TBPH
Theravance Biopharma, Inc.
YUPELRI's nebulized delivery represents a drug delivery platform differentiator for a respiratory therapy.
|
$1.01B |
$19.97
+5.44%
|
|
BHVN
Biohaven Ltd.
MoDE/TRAP and related platforms constitute drug-delivery platforms enabling targeted degradation of extracellular proteins.
|
$1.00B |
$9.51
+1.06%
|
|
VERV
Verve Therapeutics, Inc.
Verve's platform GalNAc-LNP is a proprietary drug delivery system used to target liver cells for gene-editing therapies.
|
$988.30M |
$11.13
|
|
NBTX
Nanobiotix S.A.
Curadigm and Oocuity are nanoparticle-based platforms aimed at drug delivery and neurally targeted effects, aligning with Drug Delivery Platforms.
|
$966.56M |
$20.20
-4.85%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$945.77M |
$9.57
+3.18%
|
|
SVRA
Savara Inc.
Delivery via inhalation (Drug Delivery Platform) is a core aspect of MOLBREEVI's administration method.
|
$926.41M |
$5.37
+4.27%
|
|
FLGT
Fulgent Genetics, Inc.
Drug delivery platforms including nanoencapsulation.
|
$922.86M |
$30.16
-2.25%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's use of a proprietary oral-dispensing drug-delivery technology constitutes a Drug Delivery Platform.
|
$920.66M |
$12.10
+1.85%
|
|
NTLA
Intellia Therapeutics, Inc.
Proprietary drug-delivery platform (LNP) enabling in vivo gene editing across programs.
|
$914.60M |
$8.53
-0.23%
|
|
VIR
Vir Biotechnology, Inc.
PRO-XTEN masking platform represents a drug delivery platform intended to improve safety and therapeutic index.
|
$887.68M |
$6.41
-0.47%
|
|
ABUS
Arbutus Biopharma Corporation
Their LNP delivery technology is a drug delivery platform underpinning their RNAi assets.
|
$845.39M |
$4.43
+2.55%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$803.77M |
$3.75
-0.27%
|
|
OCS
Oculis Holding AG
OPTIREACH is a drug delivery platform enabling topical therapies to reach the posterior segment.
|
$793.18M |
$18.92
-2.12%
|
|
REPL
Replimune Group, Inc.
RPx platform functions as a drug delivery platform enabling multi-gene payload immunotherapies.
|
$785.24M |
$10.07
+5.67%
|
|
GHRS
GH Research PLC
GH Research employs an inhalable drug delivery approach for GH001, representing a Drug Delivery Platforms capability.
|
$767.42M |
$14.75
-0.97%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$759.45M |
$3.35
+2.45%
|
|
KE
Kimball Electronics, Inc.
Drug delivery platforms are a targeted medical technology offering within KE's Medical CMO scope.
|
$698.95M |
$28.90
+1.16%
|
|
CTMX
CytomX Therapeutics, Inc.
PROBODY is a drug delivery platform designed to localize activity to tumors, fitting Drug Delivery Platforms.
|
$695.93M |
$4.21
+1.57%
|
|
RGNX
REGENXBIO Inc.
NAV platform involves drug delivery platform technology.
|
$669.82M |
$13.26
-1.45%
|
|
MGTX
MeiraGTx Holdings plc
Riboswitch platform represents a drug delivery platform enabling regulated transgene expression, a core technology.
|
$659.67M |
$8.21
+8.25%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$620.28M |
$6.21
+1.97%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$610.02M |
$2.25
|
|
MNPR
Monopar Therapeutics Inc.
MNPR-101 platform represents a drug delivery platform for radiopharmaceuticals, enabling targeted delivery and radionuclide conjugation.
|
$539.01M |
$87.19
-1.45%
|
|
DSGN
Design Therapeutics, Inc.
GeneTAC platform implies a drug delivery/modulation approach, aligning with a Drug Delivery Platforms category.
|
$533.60M |
$9.40
-0.11%
|
|
LXEO
Lexeo Therapeutics, Inc. Common Stock
Uses a drug delivery platform (AAV vectors) to deliver genes, constituting a drug delivery platform business line.
|
$520.03M |
$9.63
-0.93%
|
|
FDMT
4D Molecular Therapeutics, Inc.
FDMT's Therapeutic Vector Evolution platform constitutes a drug delivery platform enabling targeted, durable gene therapy delivery.
|
$513.26M |
$10.99
+2.90%
|
|
BCYC
Bicycle Therapeutics plc
Platform enables targeted delivery and payload conjugation for therapeutics (drug delivery platform).
|
$506.63M |
$7.32
+6.55%
|
|
PRME
Prime Medicine, Inc.
Leverages a drug delivery platform (universal liver LNP with GalNAc targeting) to enable in vivo gene editing.
|
$499.27M |
$3.71
-0.13%
|
|
ADCT
ADC Therapeutics S.A.
ADCT emphasizes a proprietary Drug Delivery Platform powering its ADC payloads and conjugation chemistries.
|
$487.12M |
$4.35
-0.91%
|
|
ZVRA
Zevra Therapeutics, Inc.
LAT platform enables prodrug drug delivery platforms, representing a proprietary drug-delivery platform technology.
|
$482.76M |
$8.60
+2.32%
|
|
DMAC
DiaMedica Therapeutics Inc.
DM199 represents a drug-delivery/therapeutic platform with IV administration and ongoing manufacturing development.
|
$471.40M |
$9.12
+1.05%
|
|
ENGN
enGene Holdings Inc.
DDX platform is a drug delivery technology enabling localized genetic medicines, a distinct product category.
|
$421.62M |
$8.23
+6.74%
|
|
PRTC
PureTech Health plc
Glyph platform is a drug-delivery technology enabling oral administration of therapies.
|
$412.68M |
N/A
|
|
CLPT
ClearPoint Neuro, Inc.
SmartFlow cannula represents a drug-delivery platform for targeted brain infusion, tied to cell/gene therapy delivery approaches.
|
$410.49M |
$14.42
-1.23%
|
|
AURA
Aura Biosciences, Inc.
Aura's VDC platform is a drug delivery platform enabling targeted, light-activated therapy.
|
$396.32M |
$6.38
+4.34%
|
|
LCTX
Lineage Cell Therapeutics, Inc.
Lineage emphasizes a drug delivery platform and formulation (cryopreserved thaw-and-inject formulations) enabling scalable, ready-to-administer cell therapies.
|
$390.49M |
$1.73
-0.86%
|
|
TRDA
Entrada Therapeutics, Inc.
Entrata's primary value proposition is its Drug Delivery Platform (EEV) enabling intracellular delivery of therapeutics.
|
$383.41M |
$10.10
-0.25%
|
|
ANRO
Alto Neuroscience, Inc.
Drug delivery platform to enable targeted or improved administration of Alto's CNS therapeutics (e.g., transdermal PDE4 inhibitor).
|
$365.81M |
$13.56
+1.50%
|
|
BNTC
Benitec Biopharma Inc.
The Silence and Replace platform includes a drug delivery vector approach, fitting Drug Delivery Platforms.
|
$341.65M |
$13.05
+0.93%
|
|
DCTH
Delcath Systems, Inc.
Delcath's core offering is a Drug Delivery Platform enabling hepatic delivery of chemotherapy (PHx/HEPZATO KIT) for liver-directed treatment.
|
$337.22M |
$9.63
+4.39%
|
Showing page 1 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
